

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK**

UNITED STATES OF AMERICA

Plaintiff,

v.

JANELLE HARRIS,

Defendant.

25 Civ. 6456

STIPULATION AND ORDER OF INJUNCTION, SETTLEMENT, AND DISMISSAL

WHEREAS, this Stipulation and Order of Injunction, Settlement and Dismissal (“Stipulation”) is entered into by and among plaintiff the United States of America (the “United States” or “Government”), by its attorney, Jay Clayton, United States Attorney for the Southern District of New York and defendant Janelle Harris (“Harris” or the “Defendant,” and together with the Government, the “Parties”), by her authorized representatives;

WHEREAS, Janelle Harris is a pharmacist licensed in the State of New York, and was the owner and supervising pharmacist of The Pharmacy @ LLC (“The Pharmacy”), which was a retail pharmacy located at 2541 Adam Clayton Powell Jr. Blvd. (7th Avenue), New York, New York 10039, until its closure in or about April 2023.

WHEREAS, The Pharmacy, at all times relevant to the Covered Conduct discussed herein, was registered with the Drug Enforcement Administration (“DEA”) and dispensed, among other things, Schedule II controlled substances as defined under the Controlled Substances Act (“CSA”), pursuant to DEA registration number FT4434762. *See* 21 U.S.C. § 802(6), 21 C.F.R. § 1308.12.

WHEREAS, Schedule II controlled substances are defined under the CSA as drugs that have a currently accepted medical use in the United States, but also a high potential for abuse, which may lead to severe psychological or physical dependence. *See* 21 U.S.C. § 812(b)(2).

WHEREAS, Schedule II controlled substances include, but are not limited to, opiates, opiate derivatives and their chemical equivalents, such as Oxycodone. *See* 21 U.S.C. § 812(c);

WHEREAS, the CSA establishes that, with limited exceptions, a controlled substance can only be dispensed upon a prescription from a practitioner, such as a physician. 21 U.S.C. § 829(a), (b);

WHEREAS, a prescription is legally valid under the CSA only if issued for “a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice.” 21 C.F.R. § 1306.04(a). Along with the medical practitioner issuing the prescription, a pharmacist considering whether to fill the prescription bears a “corresponding responsibility” to ensure “the proper prescribing and dispensing of controlled substances.” *Id.* “An order purporting to be a prescription issued not in the usual course of professional treatment . . . is not a prescription within the meaning and intent” of 21 U.S.C. § 829, “and the person knowingly filling such a purported prescription, as well as the person issuing it, shall be subject to the penalties provided for violations of the provisions of law relating to controlled substances.” *Id.*

WHEREAS, the Government alleges that from 2014 through 2018 (the “Covered Period”), Defendant violated the CSA and its implementing regulations by accepting and filling prescriptions for controlled substances at The Pharmacy, and by supervising employees at The Pharmacy that accepted and filled prescriptions for controlled substances, without adequately fulfilling Defendant’s responsibility to ensure that the prescriptions were for a legitimate medical

purpose. The conduct described in this Paragraph is the “Covered Conduct” for purposes of this Stipulation;

WHEREAS, contemporaneous with the filing of this Stipulation, the Government has filed a Complaint in which it is asserting claims against Defendant under the Controlled Substances Act, as amended, 21 U.S.C. §§ 801 *et seq.*;

WHEREAS, the Parties have, through this Stipulation, reached a mutually agreeable resolution addressing the claims asserted against Defendant in the Complaint for the Covered Conduct;

NOW, THEREFORE, upon the Parties’ agreement IT IS HEREBY ORDERED that:

TERMS AND CONDITIONS

1. The Parties agree that this Court has subject matter jurisdiction over this action and consent to this Court’s exercise of personal jurisdiction over each of them.
2. Defendant admits, acknowledges and accepts responsibility for the following conduct (the “Admitted Conduct”):
 - a. During the Covered Period, Harris was a pharmacist licensed in the State of New York, and the owner of The Pharmacy. In her capacity as the owner and operator of The Pharmacy, Harris was actively involved in, supervised, and was responsible for dispensing Schedule II controlled substances, as well as non-controlled prescription medications.
 - b. Harris, as a pharmacist and owner of The Pharmacy, had a duty to ensure that prescriptions filled at The Pharmacy for controlled substances were for a legitimate medical purpose before dispensation. As part of this duty, Harris was required to look for, “red flags” indicating that the controlled substances prescribed are at risk for abuse or diversion and/or not for a legitimate medical purpose. Such red flags include, but are not limited to: prescriptions for high dosage strengths and/or for large quantities of controlled substances; cash payments for controlled substances; sequential prescription numbers; and multiple prescriptions for controlled substances to a single individual within a short period of time.

- c. During the Covered Period, Harris and/or employees of the Pharmacy under her supervision, filled cash prescriptions at The Pharmacy for Schedule II controlled substances, such as Oxycodone, that were ultimately determined to be issued without a legitimate medical purposes and contained numerous red flags.
- d. For example, Harris, and/or employees of the Pharmacy under her supervision, filled prescriptions for Schedule II controlled substances that contained the following indicia of invalidity:
 - (1) Over a four-month period, 114 of the 115 prescriptions written by a single doctor were for 120 tablets of Oxycodone 30mg. During this period, no one from The Pharmacy called this doctor to confirm the validity of these prescriptions.
 - (2) A single individual received over 200 prescriptions of Oxycodone, all paid for in cash. These prescriptions were either written for this individual or were written for others but picked up by this individual using a fake identification card.

3. Defendant shall execute and agree to the entry of a consent judgment in favor of the Government and against Defendant in the amount of \$16,700,000, a copy of which is attached hereto as Exhibit A (the "Consent Judgment"). The Government may use the Consent Judgment to obtain a security interest in any asset or property of the Defendant, but shall not engage in other collection activity with respect to the Consent Judgment so long as Defendant fully complies with the terms of this Stipulation. Pursuant to this stipulation, Defendant agrees to pay and the Government agrees to accept the sum of \$100,000 in full satisfaction of the Consent Judgment (the "Settlement Amount"). Defendant shall pay the Settlement Amount to the Government in installments as set forth below. Defendant shall make the below-referenced payments in accordance with instructions to be provided by the Financial Litigation Unit of the United States Attorney's Office for the Southern District of New York. The entirety of the Settlement Amount is a penalty under the CSA pursuant to 21 USC § 842(c). Defendant agrees that she shall not seek indemnification from any source with respect to any portion of the Settlement Amount.

- (a) Within fourteen (14) business days of the Effective Date (defined below in Paragraph 27), Defendant shall pay the Government the sum of \$20,000, plus interest compounded annually at a rate of 4.625% accruing from the Effective Date.
- (b) On or before December 31, 2025, Defendant shall pay the Government the sum of \$20,000, plus interest compounded annually at a rate of 4.625% accruing from the Effective Date.
- (c) On or before December 31, 2026, Defendant shall pay the Government the sum of \$20,000, plus interest compounded annually at a rate of 4.625% accruing from the Effective Date.
- (d) On or before December 31, 2027, Defendant shall pay the Government the sum of \$20,000, plus interest compounded annually at a rate of 4.625% accruing from the Effective Date.
- (e) On or before December 31, 2028, Defendant shall pay the Government the sum of \$20,000, plus interest compounded annually at a rate of 4.625% accruing from the Effective Date.

4. Should Defendant comply fully with the payment schedule set forth in Paragraph 3 above as well as the other terms of this Stipulation, the Consent Judgment shall be deemed to be satisfied in full and, upon Defendant's request, the Government shall file with the Clerk of the Court and deliver to Defendant a Full Satisfaction of Judgment. In the event that Defendant fully pays the Settlement Amount earlier than as provided in the payment schedule set forth in Paragraph 3 above, and fully complies with all other terms of the Stipulation, the Consent Judgment shall be deemed to be satisfied in full and, upon Defendant's request, the Government shall file with the

Clerk of the Court and deliver to Defendant a Full Satisfaction of Judgment. Should Defendant fail to comply fully with the payment schedule set forth in Paragraph 3 above or any other term of this Stipulation, Defendant shall be in default of this Stipulation, in which case the Government may take any of the actions set forth in Paragraph 11 below.

5. As of the Effective Date, Defendant is hereby enjoined from:
 - a. For a period of 5 years, serving as a: Supervising Pharmacist, or Pharmacist-In-Charge, or otherwise supervising, managing, or controlling any pharmacists, or pharmacists in charge; or holding any of the supervisory responsibilities set forth in N.Y. State Ed. Law Art. 137 § 6808 or any other analogous state statutes, regulations and rules at any pharmacy that purchases, stores, or dispenses controlled substances; and
 - b. For a period of 7 years, owning (in whole or in part), controlling, operating, or managing a pharmacy that purchases, stores, or dispenses controlled substances.

6. For a period of five years from the Effective Date (the “Notice Period”), if Defendant is employed, in any capacity, in a pharmacy during the Notice Period, she shall provide written notice to the Government, within 5 business days following the start of her employment, of the name and address of such pharmacy. If such employment is terminated, for any reason, during the Notice Period, Defendant shall provide written notice to the Government of such termination and the reason for her termination within 5 business days following her last day of employment. Notice to the Government shall be provided in the manner set forth in Paragraph 26 below.

7. Defendant agrees to cooperate fully and truthfully with the United States' investigation of individuals and entities not released in this Stipulation. Upon reasonable notice, Defendant shall encourage, and agrees not to impair, the cooperation of others, and shall use her best efforts to make available, and encourage, the cooperation of former The Pharmacy employees for interviews and testimony, consistent with the rights and privileges of such individuals. Defendant further agrees to furnish to the United States, upon request, complete and unredacted copies of all non-privileged documents, reports, memoranda of interviews, and records in her possession, custody, or control concerning any investigation of the Covered Conduct that she has undertaken, or that has been performed by another on her behalf.

8. Subject to the exceptions in Paragraph 10 (concerning reserved claims) below and subject to Paragraph 11 (concerning default) and Paragraph 14 (concerning bankruptcy proceedings) below, and Paragraph 15 (concerning disclosure of financial information) below, and conditioned on Defendant's full compliance with the terms of this Stipulation, including full payment of the Settlement Amount to the United States pursuant to Paragraph 3 above, the United States releases Defendant from any civil or administrative monetary claim that the United States has for the Covered Conduct under the CSA, 21 U.S.C. § 801 *et seq.* For avoidance of doubt, this Stipulation does not release any current or former officer, director, employee, or agent of Defendant or The Pharmacy (other than Defendant) from liability of any kind.

9. Defendant fully and finally releases the United States, its agencies, officers, employees, servants, and agents from any claims (including attorneys' fees, costs, and expenses of every kind and however denominated) that Defendant has asserted, could have asserted, or may assert in the future against the United States, its agencies, officers, employees, servants, or agents

related to the Covered Conduct or the United States' investigation, prosecution and settlement thereof.

10. Notwithstanding the releases given in Paragraph 8 above, or any other term of this Stipulation, the following claims of the Government are specifically reserved and are not released by this Stipulation:

- a. any liability arising under Title 26, United States Code (Internal Revenue Code);
- b. any criminal liability;
- c. except as explicitly stated in this Stipulation, any administrative liability or enforcement right, including but not limited to the suspension or debarment rights of any federal agency;
- d. any liability to the United States (or its agencies) for any conduct other than the Covered Conduct;
- e. any liability based upon obligations created by this Stipulation; and
- f. any liability of individuals (other than Defendant).

11. The Settlement Amount represents the amount the United States is willing to accept in compromise of its civil claims arising from the Covered Conduct, due solely to Defendant's financial condition as reflected in the Financial Disclosures referenced in Paragraph 15 below. Defendant shall be in default of this Stipulation if Defendant fails to pay the Settlement Amount as provided in the payment schedule set forth in Paragraph 3 above or if it fails to comply materially with any other term of this Stipulation that applies to it ("Default"). The Government will provide a written Notice of Default to Defendant of any Default in the manner set forth in Paragraph 26 below. Defendant shall then have an opportunity to cure the Default within seven

(7) calendar days from the date of receipt of the Notice of Default by making the payment due under the payment schedule and paying any additional interest accruing under the Stipulation up to the date of payment. If Defendant fails to cure the Default within seven (7) calendar days of receiving the Notice of Default and in the absence of an agreement with the United States to a modified payment schedule (“Uncured Default”), the remaining unpaid balance of the Settlement Amount shall become immediately due and payable, and interest on the remaining unpaid balance shall thereafter accrue at the rate of 12% per annum, compounded daily from the date of Default, on the remaining unpaid total (principal and interest balance). In the event of an Uncured Default, the United States may initiate a collection action or take any other action with respect to the unpaid portion of the amount specified in the Consent Judgment attached hereto as Exhibit A. Defendant also agrees that the United States, at its sole discretion, may (i) retain any payments previously made, rescind this Stipulation, and reinstate the claims asserted against Defendant in the Government Complaint or bring any civil and/or administrative claim, action, or proceeding against Defendant for the claims that would otherwise be covered by the releases provided in Paragraph 8 above, with any recovery reduced by the amount of any payments previously made by Defendant to the United States under this Stipulation; (ii) take any action to enforce this Stipulation in a new action or by reinstating the Government Complaint; (iii) offset the remaining unpaid balance from any amounts due and owing to Defendant and/or affiliated companies by any department, agency, or agent of the United States at the time of Default or subsequently; and/or (iv) exercise any other right granted by law, or under the terms of this Stipulation, or recognizable at common law or in equity. The United States shall be entitled to any other rights granted by law or in equity by reason of Default, including referral of this matter for private collection. In the event the United States pursues a collection action, Defendant agrees immediately to pay the

United States the greater of (i) a ten-percent (10%) surcharge of the amount collected, as allowed by 28 U.S.C. § 3011(a), or (ii) the United States' reasonable attorneys' fees and expenses incurred in such an action. In the event that the United States opts to rescind this Stipulation pursuant to this paragraph, Defendant waives and agrees not to plead, argue, or otherwise raise any defenses of statute of limitations, laches, estoppel or similar theories, to any civil or administrative claims that (i) are filed by the United States against Defendant within 120 days of written notification that this Stipulation has been rescinded, and (ii) relate to the Covered Conduct, except to the extent these defenses were available on November 3, 2020. Defendant agrees not to contest any offset, recoupment, and/or collection action undertaken by the United States pursuant to this paragraph, either administratively or in any state or federal court, except on the grounds of actual payment to the United States.

12. Defendant, having truthfully admitted to the Admitted Conduct set forth in Paragraph 2 hereof, agrees it shall not, through her attorneys, agents, or employees, make any public statement, including but not limited to, any statement in a press release, social media forum, or website, that contradicts or is inconsistent with the Admitted Conduct or suggests that the Admitted Conduct is not wrongful (a "Contradictory Statement"). Any Contradictory Statement by Defendant, her attorneys, agents, or employees, shall constitute a violation of this Stipulation, thereby authorizing the Government to pursue any of the remedies set forth in Paragraph 11 hereof, or seek other appropriate relief from the Court. Before pursuing any remedy, the Government shall notify Defendant that it has determined that Defendant has made a Contradictory Statement. Upon receiving notice from the Government, Defendant may cure the violation by repudiating the Contradictory Statement in a press release or other public statement within four business days. If Defendant learns of a potential Contradictory Statement by her attorneys, agents, or employees,

Defendant must notify the Government of the statement within 24 hours. The decision as to whether any statement constitutes a Contradictory Statement or will be imputed to Defendant for the purpose of this Stipulation, or whether Defendant adequately repudiated a Contradictory Statement to cure a violation of this Stipulation, shall be within the sole discretion of the Government. Consistent with this provision, Defendant may raise defenses and/or assert affirmative claims or defenses in any proceeding brought by private and/or public parties, so long as doing so would not contradict or be inconsistent with the Admitted Conduct.

13. Defendant waives and shall not assert any defenses Defendant may have to any criminal prosecution or administrative action relating to the Covered Conduct that may be based in whole or in part on a contention that, under the Double Jeopardy Clause in the Fifth Amendment of the Constitution, or under the Excessive Fines Clause in the Eighth Amendment of the Constitution, this Stipulation bars a remedy sought in such criminal prosecution or administrative action.

14. In exchange for valuable consideration provided in this Stipulation, Defendant acknowledges the following:

- a. Defendant has reviewed her financial situation and warrants that she is solvent within the meaning of 11 U.S.C. §§ 547(b)(3) and 548(a)(1)(B)(ii)(I)
- b. In evaluating whether to execute this Agreement, the Parties intend that the mutual promises, covenants, and obligations set forth herein constitute a contemporaneous exchange for new value given to Defendant, within the meaning of 11 U.S.C. § 547(c)(1), and the Parties conclude that these mutual promises, covenants, and obligations do, in fact, constitute such a contemporaneous exchange.

- c. The mutual promises, covenants, and obligations set forth herein are intended by the Parties to, and do in fact, constitute a reasonably equivalent exchange of value.
- d. The Parties do not intend to hinder, delay, or defraud any entity to which Defendant was or became indebted on or after the date of any transfer contemplated in this Stipulation, within the meaning of 11 U.S.C. § 548(a)(1).
- e. If Defendant's obligations under this Stipulation are avoided for any reason (including but not limited to through the exercise of a trustee's avoidance powers under the Bankruptcy Code) or if, before the Settlement Amount is paid in full, Defendant or a third party commences a case, proceeding, or other action under any law relating to bankruptcy, insolvency, reorganization, or relief of debtors seeking any order for relief of Defendant's debts, or to adjudicate Defendant as bankrupt or insolvent, or seeking appointment of a receiver, trustee, custodian, or other similar official for Defendant or for all or any substantial part of Defendant's assets:
 - (1) the United States may rescind the releases in this Stipulation and bring any civil and/or administrative claim, action, or proceeding against Defendant for the claims that would otherwise be covered by the releases provided in Paragraph 8 above;
 - (2) the United States has an undisputed, noncontingent, and liquidated allowed claim against Defendant in the amount of \$16,700,000, less any payments received pursuant to the Stipulation, provided, however, that such payments are not otherwise avoided and recovered from the United States by

Defendant, a receiver, trustee, custodian, or other similar official for Defendant; and

- f. Defendant agrees that any civil and/or administrative claim, action, or proceeding brought by the United States under Paragraph 14(e) above is not subject to an “automatic stay” pursuant to 11 U.S.C. § 362(a) because it would be an exercise of the United States’ police and regulatory power. Defendant shall not argue or otherwise contend that the United States’ claim, action, or proceeding is subject to an automatic stay and, to the extent necessary, consents to relief from the automatic stay for cause under 11 U.S.C. § 362(d)(1). Defendant waives and shall not plead, argue, or otherwise raise any defenses under the theories of statute of limitations, laches, estoppel, or similar theories, to any such civil or administrative claim, action, or proceeding brought by the United States within 120 days of written notification to Defendant that the releases have been rescinded pursuant to this paragraph, except to the extent such defenses were available on November 3, 2020.

15. Defendant has provided sworn financial disclosures and supporting documents (“Financial Disclosures”) to the United States and the United States has relied on the accuracy and completeness of those Financial Disclosures in reaching this Stipulation. Defendant warrants that the Financial Disclosures are complete, accurate, and current. If the United States learns of asset(s) in which Defendant had an interest at the time of the execution of this Stipulation that were not disclosed in the Financial Disclosures, or if the United States learns of any false statement or misrepresentation by Defendant on, or in connection with, the Financial Disclosures, and if such nondisclosure, false statement, or misrepresentation changes the estimated net worth of Defendant

as reflected in the Financial Disclosures by \$10,000 or more, the United States may at its option: (a) rescind this Stipulation and reinstate its lawsuit based on the Covered Conduct, or (b) let the Stipulation stand and collect the full Settlement Amount plus one hundred percent (100%) of the net value of Defendant's previously undisclosed assets. Defendant agrees not to contest any collection action undertaken by the United States pursuant to this provision, and agrees that it will immediately pay the United States the greater of (i) a ten-percent (10%) surcharge of the amount collected in the collection action, as allowed by 28 U.S.C. § 3011(a), or (ii) the United States' reasonable attorneys' fees and expenses incurred in such an action. In the event that the United States pursuant to this paragraph rescinds this Stipulation, Defendant waives and agrees not to plead, argue, or otherwise raise any defenses under the theories of statute of limitations, laches, estoppel, or similar theories, to any civil or administrative claims that (a) are filed by the United States within 120 calendar days of written notification to Defendant that this Stipulation has been rescinded, and (b) relate to the Covered Conduct, except to the extent these defenses were available on November 3, 2020.

16. Defendant agrees to the following:

- a. Unallowable Costs Defined: All costs (as defined in the Federal Acquisition Regulation, 48 C.F.R. § 31.205-47) incurred by or on behalf of Defendant and her present or former employees, and agents in connection with:
 - (1) the matters covered by this Stipulation;
 - (2) the United States' audit(s) and civil investigation(s) of the matters covered by this Stipulation;
 - (3) Defendant's investigation, defense, and corrective actions undertaken in response to the United States' audit(s) and civil investigation(s) in

connection with the matters covered by this Stipulation (including attorney's fees);

- (4) the negotiation and performance of this Stipulation;
- (5) the payment Defendant makes to the United States pursuant to this Agreement,

are unallowable costs for government contracting purposes (hereinafter referred to as Unallowable Costs).

- b. Future Treatment of Unallowable Costs: Unallowable Costs will be separately determined and accounted for by Defendant, and Defendant shall not charge such Unallowable Costs directly or indirectly to any contract with the United States.
- c. Treatment of Unallowable Costs Previously Submitted for Payment: Within 90 days of the Effective Date of this Stipulation, Defendant shall identify and repay by adjustment to future claims for payment or otherwise any Unallowable Costs included in payments previously sought by Defendant from the United States. Defendant agrees that the United States, at a minimum, shall be entitled to recoup from Defendant any overpayment plus applicable interest and penalties as a result of the inclusion of such Unallowable Costs on previously submitted requests for payment. The United States, including the Department of Justice and/or the affected agencies, reserves its rights to audit, examine, or re-examine Defendant's books and records and to disagree with any calculations submitted by Defendant regarding any Unallowable Costs included in payments

previously sought by Defendant, or the effect of any such Unallowable Costs on the amount of such payments.

17. This Stipulation is intended to be for the benefit of the Parties only. The Parties do not release any claims against any other person or entity except as otherwise provided herein.

18. Each Party shall bear its own legal and other costs incurred in connection with this matter, including the preparation and performance of this Stipulation.

19. Any failure by the Government to insist upon the full or material performance of any of the provisions of this Stipulation shall not be deemed a waiver of any of the provisions hereof, and the Government, notwithstanding that failure, shall have the right thereafter to insist upon the full or material performance of any and all of the provisions of this Stipulation.

20. This Stipulation is governed by the laws of the United States. The exclusive jurisdiction and venue for any dispute relating to this Stipulation is the United States District Court for the Southern District of New York.

21. For purposes of construing this Stipulation, this Stipulation shall be deemed to have been drafted by all Parties to this Stipulation and shall not, therefore, be construed against any Party for that reason in any subsequent dispute.

22. This Stipulation constitutes the complete agreement between the Parties with respect to the subject matter hereof. This Stipulation may not be amended except by written consent of the Parties. No prior agreements, oral representations or statements shall be considered part of this Stipulation.

23. The undersigned counsel and other signatories represent and warrant that they are fully authorized to execute this Stipulation on behalf of the persons and the entities indicated below.

24. This Stipulation is binding on Defendant's successors, transferees, heirs, and assigns.

25. This Stipulation may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same Stipulation. E-mails that attach signatures in PDF form or facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this Stipulation.

26. Any notice pursuant to this Stipulation shall be in writing and shall, unless expressly provided otherwise herein, be delivered by hand, express courier, or e-mail transmission followed by postage-prepaid mail, and shall be addressed as follows:

TO THE UNITED STATES:

Jacob M. Bergman
Assistant United States Attorney
United States Attorney's Office
Southern District of New York
86 Chambers Street, Third Floor
New York, New York 10007
Email: jacob.bergman@usdoj.gov

TO DEFENDANT:

Satish V. Poondi
290 W. Mt. Pleasant Avenue
Suite 2350
Livingston, NJ 07039
Email: spoondi@trenkisabel.law

27. The effective date of this Stipulation is the date upon which the Stipulation is approved by the Court (the "Effective Date").

Agreed to by:


THE UNITED STATES OF AMERICA

Dated: New York, New York

August 5, 2025

JAY CLAYTON
United States Attorney for the
Southern District of New York

By:



JACOB M. BERGMAN
Assistant United States Attorney
86 Chambers Street, Third Floor
New York, New York 10007
Tel.: (212) 637-2776
Attorney for the United States of America

PRIVILEGED AND CONFIDENTIAL

DEFENDANT

Dated: New York, New York

May 23, 2025

DEFENDANT JANELLE HARRIS

By:



Janelle Harris


Dated: Livingston, New Jersey

5/27, 2025

TRENK ISABEL SIDDIQI &

SHANDANIAN P.C

By:



Satish V. Poondi

290 W. Mt. Pleasant Avenue


Suite 2350

Livingston, NJ 07039

Tel: (973) 535-0839

Attorneys for Defendant

SO ORDERED:



HON. JED S. RAKOFF
UNITED STATES DISTRICT JUDGE

Dated: 9/4/, 2025

Ex. A

**THE UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK**

UNITED STATES OF AMERICA,

Plaintiff,

v.

JANELLE HARRIS,

Defendant.

25 Civ. 6456

CONSENT JUDGMENT

Upon the consent of Plaintiff the United States of America and Defendant Janelle Harris, it is hereby

ORDERED, ADJUDGED and DECREED that Plaintiff the United States of America is awarded judgment in the amount of \$16,700,000 against Janelle Harris, as well as post-judgment interest at the rate of 12% per annum compounded daily.

Agreed to by:

THE UNITED STATES

Dated: New York, New York
August 5, 2025

JAY CLAYTON

Acting United States Attorney for the
Southern District of New York


By:




JACOB M. BERGMAN
Assistant United States Attorney
86 Chambers Street, Third Floor
New York, New York 10007
Tel.: (212) 637-2776
Attorney for the Government

DEFENDANT JANELLE HARRIS


Dated: 5/29, 2025

JANELLE HARRIS
By: 
Janelle Harris

Dated: Livingston, New Jersey
5/29/, 2025

TRENK ISABEL SIDDIQI &
SHANDANIAN P.C.
By: 
Satish V. Poondi
290 W. Mt. Pleasant Avenue
Suite 2350
Livingston, NJ 07039
Tel: (973) 535-0839
Attorneys for Defendant

SO ORDERED:


HON. TED S. RAKOFF
UNITED STATES DISTRICT JUDGE

Dated: 9/4/, 2025